MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12094-024-03403-w

Медицинская библиотека · Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024

SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases.

Rodríguez María-Carmen Rubio, Chen-Zhao Xin, Hernando Ovidio, Flamarique Sonia, Fernández-Letón Pedro, Campo Maider, López Mercedes, Rodríguez Maitane, Zucca Daniel, Martínez Daniel, Sánchez-Saugar Emilio, Mañeru Fernando, Ruiz-Zorrilla Juan García, de Acilu Paz García, Valero Jeannette, Montero Angel, Ciérvide Raquel, Alvarez Beatriz, García-Aranda Mariola, Alonso Rosa, de la Casa Miguel Angel, Alonso Leyre, Nuñez Mónica, Martí Jaime, Arias Fernando

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVE

This study aimed to assess the efficacy and tolerability of stereotactic body radiation therapy (SBRT) for the treatment of liver metastases.

METHODS

Patients with up to 5 liver metastases were enrolled in this prospective multicenter study and underwent SBRT. Efficacy outcomes included in-field local control (LC), progression-free survival (PFS), and overall survival (OS). Acute and late toxicities were evaluated using CTCAE v.4.0.

RESULTS

A total of 52 patients with 105 liver metastases were treated between 2015 and 2018. The most common primary tumor was colorectal cancer (72% of cases). Liver metastases were synchronous with the primary tumor diagnosis in 24 patients (46.2%), and 21 patients (40.4%) presented with other extrahepatic oligometastases. All patients underwent intensity-modulated radiation therapy (IMRT)/volumetric-modulated arc therapy (VMAT) with image-guided radiation therapy (IGRT) and respiratory gating, and a minimum biologically effective dose (BED10Gy) of 100 Gy was delivered to all lesions. With a median follow-up of 23.1 months (range: 13.4-30.9 months) since liver SBRT, the median actuarial local progression-free survival (local-PFS) was not reached. The actuarial in-field LC rates were 84.9% and 78.4% at 24 and 48 months, respectively. The median actuarial liver-PFS and distant-PFS were 11 and 10.8 months, respectively. The actuarial median overall survival (OS) was 27.7 months from SBRT and 52.5 months from metastases diagnosis. Patients with lesion diameter ≤ 5 cm had significantly better median liver-PFS (p = 0.006) and OS (p = 0.018). No acute or late toxicities of grade ≥ 3 were observed.

CONCLUSIONS

This prospective multicenter study confirms that liver SBRT is an effective alternative for the treatment of liver metastases, demonstrating high rates of local control and survival while maintaining a low toxicity profile.

Для цитирования: Rodríguez María-Carmen Rubio, Chen-Zhao Xin, Hernando Ovidio, Flamarique Sonia, Fernández-Letón Pedro, Campo Maider, López Mercedes, Rodríguez Maitane, Zucca Daniel, Martínez Daniel, Sánchez-Saugar Emilio, Mañeru Fernando, Ruiz-Zorrilla Juan García, de Acilu Paz García, Valero Jeannette, Montero Angel, Ciérvide Raquel, Alvarez Beatriz, García-Aranda Mariola, Alonso Rosa, de la Casa Miguel Angel, Alonso Leyre, Nuñez Mónica, Martí Jaime, Arias Fernando. SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases.. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2024. DOI: 10.1007/s12094-024-03403-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.